US Patent Issued to Madera Therapeutics on Nov. 4 for "Use of caseinolytic protease P function as a biomarker of drug response to imipridone-like agents" (North Carolina Inventor)

ALEXANDRIA, Va., Nov. 6 -- United States Patent no. 12,459,945, issued on Nov. 4, was assigned to Madera Therapeutics LLC (Cary, N.C.).

"Use of caseinolytic protease P function as a biomarker of drug response to imipridone-like agents" was invented by Edwin Iwanowicz (Cary, N.C.).

According to the abstract* released by the U.S. Patent & Trademark Office: "Use of caseinolytic protease P (ClpP) function and/or concentration as a biomarker for predicting the response of a neoplastic disease, preferably cancer or another disease where enhancing ClpP activity may provide a therapeutic benefit, to a compound of Formula I. In other aspects it relates to methods and kits, as well as methods of treatment involving the use of the biomarker."

The p...